About Pulmokine
Pulmokine is a company based in Rensselaer (United States) founded in 2007 by Larry Zisman was acquired by XOMA Corporation in December 2024. Pulmokine has raised $1 million across 3 funding rounds from investors including NIH, HHS and XOMA Corporation. Pulmokine offers products and services including Breathing Aid Products. Pulmokine operates in a competitive market with competitors including Actelion, Aerovate Therapeutics, Vivus, Centessa Pharmaceuticals and Biosion, among others.
- Headquarter Rensselaer, United States
- Founders Larry Zisman
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1 M (USD)
in 3 rounds
-
Latest Funding Round
$1 M (USD), Series A
Mar 03, 2015
-
Investors
NIH
& 3 more
-
Employee Count
Not available
-
Acquired by
XOMA Corporation
(Dec 02, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pulmokine
Pulmokine offers a comprehensive portfolio of products and services, including Breathing Aid Products.
Products designed to support easier breathing and respiratory health.
People of Pulmokine
Unlock access to complete
Unlock access to complete
Funding Insights of Pulmokine
Pulmokine has successfully raised a total of $1M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pulmokine
Pulmokine has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and XOMA Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed-stage life sciences investments are made in the US.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Pulmokine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pulmokine
Investment portfolio details for Pulmokine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pulmokine
Detailed financials for Pulmokine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pulmokine Comparisons
Peer comparison for Pulmokine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pulmokine
Pulmokine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Aerovate Therapeutics, Vivus, Centessa Pharmaceuticals and Biosion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for pulmonary arterial hypertension are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for obesity and sexual health
|
|
| Locked | Locked | Locked |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed.
|
Detailed competitors of Pulmokine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pulmokine
Complete news archive for Pulmokine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmokine
Pulmokine was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Pulmokine is headquartered in Rensselaer, United States. It is registered at Rensselaer, New York, United States.
Larry Zisman is the current CEO of Pulmokine. They have also founded this company.
Pulmokine is a funded company, having raised a total of $1M across 3 funding rounds to date.
Pulmokine is a pharmaceutical company focused on pulmonary disease and kinase technology. Primary indications targeted are pulmonary arterial hypertension and related disorders such as pulmonary arterial fibrosisinterstitial lung disease, sarcoidosis and lung cancer. It has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH (currently in pre-clinical phase). Future research areas include ACE2 inhibitors for PAH and a novel class of kinase inhibitors.
Pulmokine's top competitors include Aerovate Therapeutics, Actelion and Vivus.
Pulmokine offers Breathing Aid Products.
Pulmokine has 4 investors. Key investors include NIH, HHS, XOMA Corporation, and Broadview Ventures.